Abstract:Immune dysfunction in patients with multiple myeloma (MM) includes TGF-β induced dendritic cell dysfunction, regulatory T cell (Tregs)/Th17 cell imbalance, accumulation of Tregs and myeloid derived suppressor cells. These tumor-induced dysfunctions may contribute to immune escape and even suppress immune cells introduced in adoptive cellular immunotherapy. CD28 independent T cells of the effector memory (TEM) and CD45RA+ effector memory (TEMRA) population were shown to accumulate with age and contribute to the immunosuppressive tumor microenvironment in several solid tumors and hematological cancers. Especially in the CD8+ population, the loss of CD28 is associated with high cytotoxicity and regulatory function while showing high diversity and defective antigen-induced proliferation. In the CD4 subset, regulatory and senescent T cells were studied extensively, while in the CD8 positive subset their heterogeneity is still not clearly defined. Their potential immunosuppressive role and distribution in healthy individuals (HI) as well as patients with multiple myeloma (MM) remains to be observed. Furthermore, a recently characterized CD8+CD28- NK-like T cell subset showing expression of NK-related inhibitory receptors and TCR independent effector function is potentially of interest in the progression of MM. In the present study, we compared the changes of distribution of CD8+CD25+ and CD8+FOXP3+ regulatory T cells (Treg), CD28-CD57+ senescent T cells (Tsen), and CD8+KIR/NK2GA+EOMES+ NK-like T in peripheral blood (PB) between HI and patients with MM by multicolour flow cytometry (Gating strategy shown in Figure 1A). When comparing 35 HIs (Median age is 54) and 14 MM patients (Median age is 52), it was shown that there is no significant change in the proportion of senescent T cells in CD8 (P = 0.2452), TEM/CD8 (P = 0.1686) and TEMRA/CD8 (P = 0.4861) between HIs and the MM group, while both the CD25+FOXP3+ regulatory T cells of the CD4 population (P = 0.0031) and CD28-FOXP3+ regulatory T cells of the CD8 population (P = 0.0014) were shown to increase. There is no significant difference in the percentages of KIR/NK2GA+EOMES+ in the CD8 T cell and TEMRA/CD8 T cell population between HIs and the MM group. Remarkably, although there was no overall increase in senescent T cell in MM patients, senescent CD8+NK2GA+EOMES+ NK-like T cells increased in MM patients in comparison to HIs (P = 0.0068) (Figure 1B). In conclusion, the increase of regulatory T cells of both the CD4 and CD8 population as well as the increase of senescent NK-like T cells in the CD8 population potentially contributes to cancer progression through creation of suppressive microenvironments. Moreover, we found that regulatory CD8 T cells and CD8 NK-like T cells only contribute to a small part of the overall CD28- senescent T cell pool. Figure 1 Figure 1. No relevant conflicts of interest to declare.

Increased activated regulatory T cell subsets and aging Treg-like cells in multiple myeloma and monoclonal gammopathy of undetermined significance: a case control study

Levels and Clinical Significance of Regulatory B Cells and T Cells in Acute Myeloid Leukemia

Increasing CD28-FOXP3+CD8+ Treg and Senescent CD8+NK2GA+Eomes+ NK-like T Cells in Peripheral Blood of Patients with Multiple Myeloma

Quantity and apoptosis related protein levels of CD4+, CD25+, and CD127low regulatory T cells in peripheral blood of multiple myeloma patients

Imbalance of Th17 and Treg Cells in Peripheral Blood from Multiple Myeloma Patients

What Happens to Regulatory T Cells in Multiple Myeloma

[Imbalance of Treg/th17 in Bone Marrow of Patients with Multiple Myeloma].

Changes of Peripheral Blood Lymphocyte Subsets and Cytokines in Patients with Multiple Myeloma and Their Clinical Significance

Characterization of Γδ Regulatory T Cells from Peripheral Blood in Patients with Multiple Myeloma.

Correlation between abnormal expression of CD4+CD25+CD127low/-regulatory T cells and multiple myeloma

The Alteration and Clinical Significance of Th1/Th2/Th17/Treg Cells in Patients with Multiple Myeloma

Cellular immune function and its clinical implications in 45 patients with multiple myeloma

Circulating CD45RA-Foxp3++ Treg cells serve as a biomarker for predicting minimal clinical manifestations status of myasthenia gravis

Elevated Th22 As Well As Th17 Cells Associated with Therapeutic Outcome and Clinical Stage Are Potential Targets in Patients with Multiple Myeloma

Treg-derived TGF-β1 dampens cGAS-STING signaling to downregulate the expression of class I MHC complex in multiple myeloma

Analysis of Peripheral Blood T Lymphocyte Subsets in Multiple Myeloma Patients

A Stratified Therapeutic Model Incorporated with Studies on Regulatory B Cells for Elderly Patients with Newly Diagnosed Multiple Myeloma.

Increased Exhausted CD8(+) T Cells with Programmed Death-1, T-cell Immunoglobulin and Mucin-Domain-containing-3 Phenotype in Patients with Multiple Myeloma

The clinical significance of lymphocyte subsets in peripheral blood from patients with multiple myeloma

Changes of regulatory T cells in peripheral blood of patients with myasthenia gravis and the effect of immu-nosuppressive treatment

[Expression and Significance of PD-1, PD-L1 and CTLA-4 in the Bone Marrow of Patients with Multiple Myeloma]